Investors
This section contains information about Orion as an investment.
Stock exchange releases
- 7/17/2024 Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
- 7/1/2024 Inside information: Orion upgrades full-year outlook for 2024
- 7/1/2024 Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- 5/7/2024 Orion Corporation: Change in Orion Group Executive Management Board as of 31 May 2025
Press releases
- 7/25/2024 Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
- 6/3/2024 Orion is developing the Finnish life science industry in a unique collaboration project
- 4/11/2024 Orion publishes Interim Report for January–March 2024 and holds a webcast on 25 April 2024
- 3/22/2024 The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of production at the plant
